Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiotoxicity of Cancer Therapy 2: Mechanisms, Predictors, and Social Determinants of Health in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT05078190 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT05078190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05078190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiotoxicity of Cancer Therapy 2: Mechanisms, Predictors, and Social Determinants of Health in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Active, not recruiting
Start date
October 21, 2021
Completion date
October 31, 2039
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiotoxicity, cardiovascular diseases, drug-related side effects and adverse reactions